Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isobutyramide SCHEMBL8503110 | 0.97 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2PKMEPHX1KDM4E | |
| Isobutyramide SCHEMBL189761 | 0.97 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2PKMEPHX1KDM4E | |
| SCHEMBL8882808 | 0.88 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2PKMEPHX1KDM4E | |
| Dioxane SCHEMBL3231271 | 0.87 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2PKMEPHX1KDM4E | |
| Cyclohexane SCHEMBL27620246 | 0.84 | EPHX1 (0.43) | ALDH1A1EPHX1 | |
| Isobutyramide SCHEMBL28184607 | 0.82 | EPHX1 (0.32) | EPHX1 | |
| Tetrahydrofuran SCHEMBL27268317 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKM | |
| Tetrahydrofuran SCHEMBL27775685 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKM | |
| Tetrahydrofuran SCHEMBL913001 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PKM | |
| Carbamic Acid SCHEMBL2726104 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131720-A1 | PROCESS FOR THE SYNTHESIS OF HYDROXYL ARYLAMINES | XEROX CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-7482492-B2 | Cost effective method for synthesis of triarylamine compounds | XEROX CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080255389-A1 | COST EFFECTIVE METHOD FOR SYNTHESIS OF TRIARYLAMINE COMPOUNDS | XEROX CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255389-A1 | COST EFFECTIVE METHOD FOR SYNTHESIS OF TRIARYLAMINE COMPOUNDS | ADH1A, ADH1C, AADAC | ALDH1A1 90/4885SMN1; SMN2 3368/4885PKM 1258/4885 |
| US-20090131720-A1 | PROCESS FOR THE SYNTHESIS OF HYDROXYL ARYLAMINES | NAT1, AHR, AADAC | ALDH1A1 12/4885SMN1; SMN2 4255/4885PKM 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.